536MO A phase I, first-in-human, safety, pharmacokinetic, and pharmacodynamic study of oral dubermatinib (TP-0903) in patients with advanced solid tumours.
Saved in:
| Title: | 536MO A phase I, first-in-human, safety, pharmacokinetic, and pharmacodynamic study of oral dubermatinib (TP-0903) in patients with advanced solid tumours. |
|---|---|
| Authors: | Adjei, A.A.1 (AUTHOR), Beg, M.2 (AUTHOR), Melear, J.3 (AUTHOR), Thompson, J.4 (AUTHOR), Tsai, F.Y-C.5 (AUTHOR), Baranda, J.C.6 (AUTHOR), Bastos, B.7 (AUTHOR), Spira, A.8 (AUTHOR), Lou, Y.9 (AUTHOR), Seetharam, M.10 (AUTHOR), Uemura, M.11 (AUTHOR), Camidge, D.R.12 (AUTHOR), Yamamoto, N.13 (AUTHOR), Cowey, C.L.14 (AUTHOR), Doi, T.15 (AUTHOR), Anthony, S.P.16 (AUTHOR), Janat-Amsbury, M.17 (AUTHOR), Wade, M.18 (AUTHOR), Bearss, D.J.19 (AUTHOR), Sarantopoulos, J.20 (AUTHOR) |
| Source: | Annals of Oncology. 2020 Supplement 4, Vol. 31, pS469-S469. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
